CORRECTED: Emergency Nurses Association Names PDL BioPharma as a 2007 Strategic Partner

    CHICAGO, June 13 /PRNewswire/ -- The Emergency Nurses Association (ENA)
 today announced that PDL BioPharma has been named a strategic partner for
 2007. As a strategic partner, PDL BioPharma will be the exclusive sponsor
 for the ENA State Leaders December Orientation and the Emergency Nurses
 Week, October 7-13, 2007.
     "We are very pleased to announce this partnership with PDL BioPharma,"
 said Donna Mason, RN, MS, CEN, ENA President. "By partnering with ENA, PDL
 BioPharma gets a unique opportunity to show their support of the life
 saving work of emergency nurses across the county."
     Through this partnership, PDL BioPharma will help finance ongoing
 educational and professional networking activities, as well as events
 honoring nurses during emergency nurses week.
     "As a company committed to discovering, developing and marketing
 innovative therapies that will positively impact patients' lives, PDL
 BioPharma has great respect for emergency nurses' commitment to patients,
 which is exemplified by the extraordinary work they do in emergency
 departments everyday," said Jaisim Shah, senior vice president, marketing
 and business affairs, PDL BioPharma Inc. "Like our treatments for
 short-term hypertension treatment and acute myocardial infarction, these
 healthcare professionals are saving lives everyday. Through this
 partnership, we hope to raise the visibility of emergency nurses while
 showing our appreciation for everything that they do."
     In the United States and Canada, PDL BioPharma markets several
 commercial biopharmaceutical products for the hospital setting --
 Cardene(R) I.V. (http://www.pdlbiopharma.com/index.cfm?navid=32) for the
 short-term treatment of hypertension, Retavase(R)
 (http://www.pdlbiopharma.com/index.cfm?navid=35)
     for acute myocardial infarction and IV Busulfex(R)
 (http://www.pdlbiopharma.com/index.cfm?navid=37) (Black Box Warning) for
 conditioning prior to a bone marrow transplant in association with chronic
 myelogenous leukemia.
     In addition to its marketed products, PDL has a novel antibody-focused
 proprietary pipeline, with a therapeutic focus in inflammation and
 autoimmune diseases, oncology, and cardiovascular disorders. The company's
 pioneering antibody humanization technology has also enabled nine products
 to be marketed in the United States.
     About the Emergency Nurses Association
     The Emergency Nurses Association (ENA) is the only professional nursing
 association dedicated to defining the future of emergency nursing and
 emergency care through advocacy, expertise, innovation, and leadership.
 Founded in 1970, ENA serves as the voice of more than 32,000 members and
 their patients through research, publications, professional development,
 injury prevention, and patient education. Additional information is
 available at ENA's Web site, at http://www.ena.org.
 
 

SOURCE Emergency Nurses Association